Immunotherapy

Michael B. Atkins MD and Antoni Ribas MD PhD review data from key presentations on immunotherapy from the 2015 clinical oncology meeting in Chicago.

Share

Program Content

Activities

  • Nivolumab ± Ipilimumab in SCLC
    CheckMate 032: Nivolumab ± Ipilimumab With Promising Activity in Recurrent SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation